REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2024
0mins
Should l Buy ?
Source: Businesswire
Investigation of Proposed Sale: Former Louisiana Attorney General Charles C. Foti, Jr. and Kahn Swick & Foti, LLC are investigating the proposed sale of Revance Therapeutics to Crown Laboratories, focusing on whether the offered price of $3.10 per share adequately reflects the company's value.
Legal Rights and Contact Information: Shareholders who believe the transaction undervalues Revance are encouraged to contact KSF for discussions about their legal rights regarding the sale, with emphasis on the urgency due to the tender offer structure of the transaction.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
